416 related articles for article (PubMed ID: 35785165)
1. The Role of Lipid Metabolism in Gastric Cancer.
Cui MY; Yi X; Zhu DX; Wu J
Front Oncol; 2022; 12():916661. PubMed ID: 35785165
[TBL] [Abstract][Full Text] [Related]
2. Targeting Cancer Metabolism to Resensitize Chemotherapy: Potential Development of Cancer Chemosensitizers from Traditional Chinese Medicines.
Guo W; Tan HY; Chen F; Wang N; Feng Y
Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32050640
[TBL] [Abstract][Full Text] [Related]
3. Aberrant lipid metabolism reprogramming and immune microenvironment for gastric cancer: a literature review.
Cui MY; Yi X; Zhu DX; Wu J
Transl Cancer Res; 2021 Aug; 10(8):3829-3842. PubMed ID: 35116681
[TBL] [Abstract][Full Text] [Related]
4. The Role of Autophagy in Gastric Cancer Chemoresistance: Friend or Foe?
Xu JL; Yuan L; Tang YC; Xu ZY; Xu HD; Cheng XD; Qin JJ
Front Cell Dev Biol; 2020; 8():621428. PubMed ID: 33344463
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanisms of chemoresistance in gastric cancer.
Shi WJ; Gao JB
World J Gastrointest Oncol; 2016 Sep; 8(9):673-81. PubMed ID: 27672425
[TBL] [Abstract][Full Text] [Related]
6. Lipid metabolism and its implications in tumor cell plasticity and drug resistance: what we learned thus far?
Vishwa R; BharathwajChetty B; Girisa S; Aswani BS; Alqahtani MS; Abbas M; Hegde M; Kunnumakkara AB
Cancer Metastasis Rev; 2024 Mar; 43(1):293-319. PubMed ID: 38438800
[TBL] [Abstract][Full Text] [Related]
7. Novel Insights on Lipid Metabolism Alterations in Drug Resistance in Cancer.
Yang R; Yi M; Xiang B
Front Cell Dev Biol; 2022; 10():875318. PubMed ID: 35646898
[TBL] [Abstract][Full Text] [Related]
8. Lipid metabolism in cancer progression and therapeutic strategies.
Fu Y; Zou T; Shen X; Nelson PJ; Li J; Wu C; Yang J; Zheng Y; Bruns C; Zhao Y; Qin L; Dong Q
MedComm (2020); 2021 Mar; 2(1):27-59. PubMed ID: 34766135
[TBL] [Abstract][Full Text] [Related]
9. Lipid metabolism analysis in esophageal cancer and associated drug discovery.
Jiao R; Jiang W; Xu K; Luo Q; Wang L; Zhao C
J Pharm Anal; 2024 Jan; 14(1):1-15. PubMed ID: 38352954
[TBL] [Abstract][Full Text] [Related]
10. Molecular Mechanism of Resistance to Chemotherapy in Gastric Cancers, the Role of Autophagy.
Spirina LV; Avgustinovich AV; Afanas'ev SG; Cheremisina OV; Volkov MY; Choynzonov EL; Gorbunov AK; Usynin EA
Curr Drug Targets; 2020; 21(7):713-721. PubMed ID: 31775598
[TBL] [Abstract][Full Text] [Related]
11. Curbing Lipids: Impacts ON Cancer and Viral Infection.
Dutta A; Sharma-Walia N
Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717356
[TBL] [Abstract][Full Text] [Related]
12. Lipid metabolic reprogramming as an emerging mechanism of resistance to kinase inhibitors in breast cancer.
Feng WW; Kurokawa M
Cancer Drug Resist; 2020; 3(1):1-17. PubMed ID: 32226926
[TBL] [Abstract][Full Text] [Related]
13. Lipid Metabolism and Cancer.
Cheng H; Wang M; Su J; Li Y; Long J; Chu J; Wan X; Cao Y; Li Q
Life (Basel); 2022 May; 12(6):. PubMed ID: 35743814
[TBL] [Abstract][Full Text] [Related]
14. Reprogramming of Lipid Metabolism in Lung Cancer: An Overview with Focus on EGFR-Mutated Non-Small Cell Lung Cancer.
Eltayeb K; La Monica S; Tiseo M; Alfieri R; Fumarola C
Cells; 2022 Jan; 11(3):. PubMed ID: 35159223
[TBL] [Abstract][Full Text] [Related]
15. RUNX2 Reverses p53-Induced Chemotherapy Resistance in Gastric Cancer.
Huang Y; Liang L; Zhao YX; Yao BH; Zhang RM; Song L; Zhang ZT
Pharmgenomics Pers Med; 2023; 16():253-261. PubMed ID: 37009416
[TBL] [Abstract][Full Text] [Related]
16. Metabolic reprogramming results in abnormal glycolysis in gastric cancer: a review.
Liu Y; Zhang Z; Wang J; Chen C; Tang X; Zhu J; Liu J
Onco Targets Ther; 2019; 12():1195-1204. PubMed ID: 30863087
[TBL] [Abstract][Full Text] [Related]
17. Positive regulation of prostate cancer cell growth by lipid droplet forming and processing enzymes DGAT1 and ABHD5.
Mitra R; Le TT; Gorjala P; Goodman OB
BMC Cancer; 2017 Sep; 17(1):631. PubMed ID: 28877685
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Reprogramming of Chemoresistant Cancer Cells and the Potential Significance of Metabolic Regulation in the Reversal of Cancer Chemoresistance.
Chen X; Chen S; Yu D
Metabolites; 2020 Jul; 10(7):. PubMed ID: 32708822
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer.
Huang Q; Wang Q; Li D; Wei X; Jia Y; Zhang Z; Ai B; Cao X; Guo T; Liao Y
J Exp Clin Cancer Res; 2019 Mar; 38(1):129. PubMed ID: 30876460
[TBL] [Abstract][Full Text] [Related]
20. Aberrant lipid metabolism in cancer cells - the role of oncolipid-activated signaling.
Ray U; Roy SS
FEBS J; 2018 Feb; 285(3):432-443. PubMed ID: 28971574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
